Continuous Glucose Monitoring Metrics in High-Risk Pregnant Women with Type 2 Diabetes
Diabetes Technology & Therapeutics · 2023
DOI: 10.1089/dia.2023.0300 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Diabetes Technology & Therapeutics, 2023. Verfasst von Anna McLean und 4 weiteren Autor:innen. Beteiligte Einrichtung: Wellbeing and Preventable Chronic Disease Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Pregnancy in Diabetics, Hypoglycemia. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Objective
To describe glucose metrics in a high-risk population of women with type 2 diabetes (T2DM) in pregnancy and to explore the associations with neonatal outcomes. Research Design and Methods: Prospective observational study of 57 women. Continuous glucose monitoring (CGM) trajectories were determined from metrics collected in early and late gestation using the first and last two (mean 16 and 35) weeks of Freestyle Libre data. Logistic regression was used to examine associations of CGM metrics with neonatal hypoglycemia (glucose 90th percentile for gestational age and sex). Pregnancy-specific target glucose range was 3.5–7.8 mmol/L (63–140 mg/dL).
Results
Forty-one women used CGM for 15 weeks (mean age 33 years, 73% Aboriginal or Torres Strait Islander, 32% living remotely). There was limited change in average metrics from early to late pregnancy. For the subgroup with sensor use >50% ( n = 29), mean time in range (TIR) increased by 9%, time above range reduced by 12%, average glucose reduced by 1 mmol/L, and time below range increased by 3%. Neonatal hypoglycemia was associated with most CGM metrics, HbA1c and CGM targets, particularly those from late pregnancy. LGA was associated with hyperglycemic metrics from early pregnancy. Each 1% increase TIR was associated with a 4%–5% reduction in risk of neonatal complications.
Conclusion
In this high-risk group of women with T2DM, CGM metrics only improved during pregnancy in those with greater sensor use and were associated with LGA in early pregnancy and neonatal hypoglycemia throughout. Culturally appropriate health care strategies are critical for successful use of CGM technology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wellbeing and Preventable Chronic Disease Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia.
- Endocrinology Department, Cairns Hospital, Cairns, Australia.
- Norwich Medical School, University of East Anglia, Norwich, United Kingdom.
- Endocrinology Department, Royal Darwin Hospital, Darwin, Australia.
ORCID-Profile: Anna McLean
Zitieren
APA
McLean, A., Barr, E., Tabuai, G., Murphy, H. R., & Maple-Brown, L. (2023). Continuous Glucose Monitoring Metrics in High-Risk Pregnant Women with Type 2 Diabetes. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2023.0300
Vancouver
McLean A, Barr E, Tabuai G, Murphy HR, Maple-Brown L. Continuous Glucose Monitoring Metrics in High-Risk Pregnant Women with Type 2 Diabetes. Diabetes Technology & Therapeutics. 2023. doi:10.1089/dia.2023.0300
BibTeX
@article{McLean2023,
author = {McLean, Anna and Barr, Elizabeth and Tabuai, Georgina and Murphy, Helen R and Maple-Brown, Louise},
title = {Continuous Glucose Monitoring Metrics in High-Risk Pregnant Women with Type 2 Diabetes},
journal = {Diabetes Technology & Therapeutics},
year = {2023},
doi = {10.1089/dia.2023.0300}
}
EUVIMED